Document is current
Any future updates will be listed below
-
Authors
Feng, Jingjing
Huo, Dawei
Hong, Ruimin
Jin, Xuexiao https://orcid.org/0000-0001-5402-5623
Cao, Heng
Shao, Mi
Wen, Rui
Zhang, Qiqi
Zhang, Mingming
Fu, Shan
Wang, Dongrui
Xu, Huijun
Wei, Guoqing
Cui, Jiazhen
Huang, Simao
Cui, Dawei
Chang, Alex Hongsheng https://orcid.org/0000-0002-7572-309X
Liu, Zhihong https://orcid.org/0000-0001-6093-0726
Lu, Linrong https://orcid.org/0000-0002-0171-4115
Lin, Jin https://orcid.org/0000-0002-9970-9380
Hu, Yongxian https://orcid.org/0000-0001-9564-1852
Huang, He https://orcid.org/0000-0002-2723-1621
- License Information
-
More Information
Article History
Received: 18 April 2025
Accepted: 31 July 2025
First Online: 24 September 2025
Competing interests
: A.H.C. is a founding member of Shanghai YaKe Biotechnology, Ltd., a biotechnology company focusing on research and development of tumor cellular immunotherapy. The remaining authors declare no conflicts of interest.
